Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypoglycemic Regimens vs Premixed Insulin in T2DM
NCT05545800Phase 3Unknown
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin, insulin glargine, insulin degludec, liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Xiangya Hospital, Central South University. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05545800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05545800.